Adenine phosphoribosyltransferase (APRT) deficiency in humans is an autosomal recessive syndrome characterized by the urinary excretion of adenine and the highly insoluble compound 2,8-dihydroxyadenine (DHA) that can produce kidney stones or renal failure. Targeted homologous recombination in embryonic stem cells was used to produce mice that lack APRT. Mice homozygous for a null Aprt allele excrete adenine and DHA crystals in the urine. Renal histopathology showed extensive tubular dilation, inflammation, necrosis, and fibrosis that varied in severity between different mouse backgrounds. Thus, biochemical and histological changes in these mice mimic the human disease and provide a suitable model of human hereditary nephrolithiasis.Adenine phosphoribosyltransferase (APRT; EC 2.4.2.7) is a ubiquitously expressed enzyme that catalyzes the synthesis of adenosine monophosphate from adenine and 5-phosphoribosyl-1-pyrophosphate (1). Adenine is produced endogenously as a by-product of the polyamine pathway and by the reaction of adenosine with S-adenosylhomocysteine hydrolase (2, 3). In the absence of functional APRT, adenine is oxidized by xanthine dehydrogenase (XDH; EC 1.2.3.2), by an 8-hydroxy intermediate, to 2,8-dihydroxyadenine (DHA) (4). The sparingly soluble nature of DHA at the normal pH of human urine (5) results in the excretion of DHA crystals in the urine and, frequently, the deposition of DHA stones in the kidneys. Adenine, which is not normally found in the urine at detectable levels, is also excreted.Clinical symptoms of APRT deficiency vary from benign to life-threatening and may be present from birth or have onset late in life (reviewed in ref.